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Influenza viruses are respiratory pathogens known to infect a wide variety of vertebrate species 
and cause annual epidemics in addition to sporadic pandemics. These viruses belong to the 
Orthomyxoviridae family and are divided into three genera – influenzas A, B, and C. In 2011, a 
novel virus sharing approximately 50% amino acid homology with human influenza C virus 
(ICV) was isolated from pigs showing symptoms of respiratory infection in Oklahoma. Further 
studies revealed that this newly isolated virus was unable to reassort with human ICV to produce 
viable progeny and exhibited no cross-recognition with human ICV polyclonal antibodies. These 
findings suggested the virus isolate was genetically and antigenically divergent from human 
ICV, thus a new genus within the Orthomyxoviridae family was established, termed influenza D 
virus (IDV). In 2017 and 2018, the Animal Influenza Ecology and Epidemiology Research 
Program at The Ohio State University collected nasal swabs and nasal wipes from swine being 
sold at jackpot shows and identified several IDV strains. To investigate the potential for IDV 
transmission to humans, we infected primary human nasal epithelial cells (hNECs) with three 
swine isolates of IDV (D/swine/Kentucky/17TOSU1262/2017, 
D/swine/Ohio/18TOSU0287/2018, and D/swine/Kentucky/17SW1262/2017) and determined 
infectious virus production and epithelial cell tropism at temperatures consistent with the upper 
(32˚C) and lower (37˚C) human respiratory tract. The IDV strains replicated to high infectious 
virus titer in MDCK cells and hNEC cultures, indicating they were capable of infecting cells of 
the human respiratory tract. A comparison of chemokine and cytokine induction in hNEC 
cultures following IDV infection demonstrated decreased expression in 50% of factors tested 
when compared to ICV infected cultures. High titer replication in conjunction with repression of 
the innate immune response suggests IDV is capable of human infection. These studies provide a 
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better understanding of the ability of IDV to infect and cause disease in humans and suggest 
increased surveillance for this genus of influenza virus is necessary. 
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Introduction to Influenza D Virus 
Influenza viruses are negative-sense, single-stranded, segmented RNA viruses belonging 
to the Orthomyxoviridae family. Prior to 2011, only three genera of influenza virus were known 
to exist, influenza A (IAV), B (IBV), and C (ICV) viruses1. IAV and IBV both possess 8 
genomic segments that encode 11 proteins, including hemagglutinin (HA), neuraminidase (NA), 
matrix 1 (M1), matrix 2, nucleoprotein (NP), non-structural protein 1, non-structural protein 2, 
polymerase acid protein, polymerase basic protein 1 (PB1), polymerase basic protein 2, and 
polymerase basic protein 1-F22. For IAV and IBV, HA serves to mediate receptor recognition 
and membrane fusion, whereas NA possesses receptor destroying functions3,4. This is in contrast 
to ICV whose genome consists of 7 genomic segments and encodes only one surface protein, 
hemagglutinin-esterase-fusion glycoprotein (HEF). The HEF protein combines the functions of 
the analogous HA and NA proteins, allowing for receptor binding, receptor destroying, and 
membrane fusion4.  
Influenza viruses are classified into the three genera according to two criteria5. First is the 
sequence homology of highly conserved proteins. Typically in phylogenetic analyses, the 
nucleotide sequence of either PB1 or NP and M1 proteins are compared in order to establish 
evolutionary relationships5–7. These proteins are used for this purpose due to their low intergenic 
sequence homology (20-30%) but high intragenic sequence homology (>85%)1. The second 
criterion is that viruses within the same genus must be able to reassort and produce viable 
progeny5.  
In 2011, a novel virus was isolated by Hause et al.7 from nasal swabs collected from 
clinically ill pigs. Observation of the virus via electron microscopy revealed enveloped, 
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pleomorphic particles with dense projections on their surface, suggesting the virus belonged to 
the Orthomyxoviridae family. Enzyme assays demonstrated the virus lacked detectable 
neuraminidase activity but possessed O-acetylesterase, consistent with viruses in the ICV genus. 
Supporting this assertion was the discovery that the new virus had 7 genomic segments. As a 
result, the virus was provisionally named C/swine/Oklahoma/1334/2011 (C/OK). However, real-
time reverse transcription PCR (qRT-PCR) and RT-PCR analyses were negative for IAV, IBV, 
and ICV strains7. 
In order to definitively classify C/OK into one of the influenza genera, the amino acid 
sequence of its PB1 protein was aligned to that of several human IAV, IBV, and ICVs7. C/OK 
was found to share 69-72% mean pairwise identity to ICVs. This level of identity is comparable 
to the level of homology observed between IAV and IBV PB1 proteins (61%) and is 
significantly lower than the high identity typically observed between viruses belonging to the 
same genus (reaching 90% in PB1s from intrasubtype IAVs). Alignment of PB1 sequences from 
C/OK and IAV and IBV demonstrated further diminished mean pairwise identity (39-41%). 
Similarly, when the amino acid sequence identity of the C/OK NP and M1 proteins were 
compared to other ICVs, only 38-41% identity was observed, well below the typical intragenic 
homology of >85%. When comparing overall amino acid identity, C/OK was found to be only 
50% homologous to human ICV. Therefore, though these experiments suggested C/OK was most 
closely related to ICV, they also indicated that C/OK was distinct when compared to human 
ICVs. 
To further clarify its taxonomic status, Hause et al.5 conducted in vitro reassortment 
assays testing the ability of C/OK to productively reassort with human ICV. For these 
experiments, two human ICVs (C/Taylor/1947 and C/Johannesburg/66), C/OK, and a bovine 
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isolate closely related to C/OK (C/660) were selected. Following coinfection, plaques were 
picked and their full genomes sequenced to identify the presence of potential reassortant viruses. 
Though reassortant viruses were found following coinfection with either the two human viruses 
or the two non-human isolates, no reassortants were generated during coinfection with 
combinations of human and non-human viruses. This led the researchers to conclude that these 
non-human ICVs were genetically distinct from human ICVs. Furthermore, Hause et al. also 
demonstrated that C/OK could not be cross-recognized by polyclonal antisera generated in 
response to representative IAV, IBV, or ICV infections, suggesting that C/OK was also 
antigenically distinct from human ICV5. Together, the low sequence homology between the PB1, 
NP, and M1 proteins of C/OK and other human ICVs, in addition to C/OK’s inability to reassort 
with human ICV and produce viable progeny led to the conclusion that C/OK meets neither 
criteria to be classified in the ICV genus. As a result, a fourth influenza genus in the 
Orthomyxoviridae family was proposed, influenza D virus (IDV)5.  
Cellular Tropism of Influenza D Virus 
 The evolutionary relationship of IDV to ICV is evident in their shared primary receptor, 
9-O-acetyl-N-acetylneuraminic acid (Neu5,9Ac2). However, several studies have shown that 
IDV possesses a broader cellular tropism than ICV6–8. Structural modeling of IDV and ICV HEF 
proteins demonstrated that they share an enzymatic active site, leading to their consistency in 
receptor choice7,8. Despite this, modeling analysis also revealed variations in the receptor-
binding pocket (RBP)6,7, which is perhaps not surprising given the 53% sequence identity 
observed between D/OK (previously known as C/OK) and human ICV HEF proteins7. In the 
ICV HEF protein RBP, a negatively-charged D269 forms a salt bridge with the positively-
charged K235, effectively closing off the end of the pocket. The equivalent amino acids in the 
5 
 
IDV HEF protein RBP cannot form this bridge, allowing for the generation of an open channel. 
The resulting open receptor binding cavity may allow IDV to recognize a larger repertoire of 
glycans which can then be used as cellular receptors6,8. Support for this theory has already come 
from research demonstrating the ability of IDV to recognize both Neu5,9Ac2 and 9-O-acetyl-N-
glycolylneuraminic acid (which differs from Neu5,9Ac2 by the addition of an oxygen at the C5 
position), whereas ICV strongly prefers Neu5,9Ac29. Additionally, IDV lacks a glycosylation 
site at N233, located at the upper part of the RBP6. By removing this site, IDV HEF has 
increased access to the receptor, likely contributing to the broader cellular tropism of IDV6. 
Another possible influence on tropism is the IDV HEF protein’s stronger binding capacity for 
Neu5,9Ac2 compared to the ICV HEF protein8.  
 Recognition of Neu5,9Ac2 by IDV is the primary driver of cellular susceptibility to 
infection. O-acetylated sialic acids are distributed throughout the respiratory tract, however 
Neu5,9Ac2 is found specifically in the trachea (submucosal glands and apical surface) and lungs 
(alveolar pneumocytes and endothelia of vessels) of humans6,8,10. Neu5,9Ac2 has also been 
shown to be distributed in the tracheal epithelial cells of pigs, horses, dogs, mice, and Peking 
ducks, and in the lungs of ferrets, mice, and Peking ducks10.  Consistent with these findings, IDV 
has been shown to replicate in the lower respiratory tract of pigs11–13 and cattle14. 
Characterization of Neu5,9Ac2 distribution in the far upper respiratory tract, such as the nasal 
cavity, has yet to be conducted. However, IDV replication in the upper respiratory tract of 
pigs7,11,12 and cattle13 suggests the presence of Neu5,9Ac2 on these tissues as well. Overall, the 
tissue distribution of Neu5,9Ac2 within the respiratory tract and the cellular preference of IDV 
has yet to be fully elucidated. 
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Disease Presentation of Influenza D Virus 
 Clinical symptoms of influenza infections can range from mild, as seen typically in ICV 
infections, to severe and potentially life-threatening, which can occur in extreme cases of IAV or 
IBV infection9. Disease presentation because of influenza infection is thought to be tied to 
replication in the upper versus lower respiratory tract. Viruses capable of replicating at core body 
temperature (37˚C) are able to cause pathology in the lungs, potentially leading to severe 
disease15. This is in contrast to viruses whose infection is limited to the upper respiratory tract 
(32˚C), which have reduced or nonexistent replication in the lungs and thus do not induce serious 
illness15.  
Currently, the health implications of IDV infection in humans are unknown. The impact 
of IDV on non-human animals, however, has been investigated9,16. Typically, IDV infection in 
swine and cattle is associated with mild upper respiratory illness7,17–19 associated with symptoms 
such as rhinitis and tracheitis20, dry cough, nasal discharge, and depression17. IDV infection of 
the lower respiratory tract has been reported in cattle and swine as well, resulting in mild to 
moderate disease characterized by fever and lung lesions12,18. However, experimental hosts like 
guinea pigs21 and ferrets7 do not develop clinical signs of disease despite seroconverting and 
supporting viral replication. 
It has also been speculated that IDV alone is not sufficient to cause severe disease, but 
may play a significant role in bovine respiratory disease (BRD)22. BRD is the most economically 
devastating affliction in the cattle industry, resulting in over a billion dollars in losses per year in 
the U.S. alone22. This disease is thought to result from the complex interplay between host, 
pathogens, and the environment. The leading theory suggests that stress induced by transport or 
other environmental factors followed by viral infection disrupts the airway epithelium, creating 
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opportunities for severe secondary infection of the respiratory tract by other viruses, bacteria, or 
parasites22,23. Several viruses, including bovine adenovirus 3 and bovine rhinitis A virus, have 
been implicated in the pathology associated with BRD24. IDV is also thought to play a role in 
these interactions due to its frequent detection in cattle presenting with BRD5,22,24,25.  
Route of Transmission 
 Facilitated by its ability to replicate in the upper and lower respiratory tract, the primary 
route of transmission for IDV is via direct contact7,12,17. In a study conducted by Lee et al.12, all 
non-infected pigs commingled with IDV infected pigs seroconverted within 6 days, though no 
live virus was present in nasal swabs or bronchoalveolar lavage fluid samples12. These findings 
are in agreement with a study conducted in cattle where all naïve calves commingled with 
infected calves seroconverted within 6 days post exposure17. Of more zoonotic concern, IDV was 
able to transmit via direct contact between infected and non-infected ferrets7. Ferrets are 
commonly used as animal models for human respiratory diseases, particularly influenza, due to 
their similar lung physiology and ability to mimic the clinical presentation of human infection26–
28. As a result, the ability of IDV to spread between ferrets suggests the potential for human 
transmission7.  
 Other potential modes of transmission contributing to the spread of IDV are aerosols and 
respiratory droplets. In a study conducted by Salem et al.18, non-infected calves separated by a 
three meter distance from directly inoculated calves began shedding IDV in nasal secretions ten 
days after the infected calves began to shed virus18. As part of the same study, IDV genome was 
detected in air samples collected from the inoculated group area, the space between the directly-
inoculated and non-infected animals, and the non-infected animal area18. Additionally, in the 
ferret study conducted by Hause et al.7, 1/3 of ferrets exposed to respiratory droplets 
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seroconverted, though none shed detectable virus. These results suggest that replication of IDV 
in the upper respiratory tract allows it to be spread by respiratory means in addition to direct 
contact.  
Host Range and Geographic Distribution of Influenza D Virus 
The ubiquitous presence of 9-O-acetyl sialic acid in the respiratory tract of animals 
provides IDV with a wide host and cell range. Currently IDV is known to naturally infect 
swine11,29–31, wild boar29, cattle30, goats31–33, sheep30,32,33, camels34,35, and horses36 with virus or 
antibodies being observed in cattle and swine in the U.S. 6,7,25, Italy11,37–39, U.K.40, France29,32,41, 
Ireland42, China31,43, Africa34, Luxembourg44, Turkey45, Mexico22, Japan46,47, Argentina48, and 
Canada33. Under experimental conditions mice49, guinea pigs21, and ferrets7 have also been found 
to be susceptible to infection.  
 Despite being originally isolated from swine, infrequent isolation of IDV from pigs, low 
RT-PCR positivity to IDV in pigs, and multiple serological surveys demonstrating low 
seropositivity to IDV suggested that swine are not the primary host of the virus 5,7,11,30,32. 
Alternatively, screening of bovine sera among U.S. cattle herds and newborn calves 
demonstrated 87.5%50 and 94-98% 6,25,51 seropositivity respectively. Overall, the magnitude of 
IDV seropositivity seen in cattle is comparable to IAV seropositivity in waterfowl, the 
established reservoir for IAV5. Therefore, these high and widespread antibody titers in cattle 
suggest bovines are the natural host of IDV. This makes IDV the first influenza genus to use 
cattle as a reservoir52,53.  
Pandemic Potential of Influenza D Virus 
 The non-human primary host of IDV becomes significant when comparing the genera of 
influenza viruses. Unlike IDV, humans are the primary host and reservoir for IBV and ICV. In 
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addition, though IBV and ICV are capable of transmitting to animals, they do so rarely1,4,7,11. 
Similar to IDV and in contrast to IBV and ICV, IAV possesses a non-human natural host, 
waterfowl, and several maintenance hosts, including humans, swine, seals, mink, horses, dogs, 
birds, and others6,54. IAV is able to attain this diversity of host species because it has multiple 
genetically distinct subtypes including 18 HA and 11 NA subtypes, all combinations of which 
can be found in waterfowl6,12. Its wide host range and the vast genetic diversity generated by 
these multiple subtypes affords IAV its pandemic potential7.  
When two distinct IAVs infect the same cell, the 8 genomic segments of each virus are 
replicated simultaneously. In the process of packaging the genomic segments into new virions it 
is possible for reassortment to occur in which the genetic components of the first virus are 
shuffled with the second. As a result, a new virus is generated containing segments derived from 
both parent viruses. When this process leads to the generation of an IAV that can infect humans 
but encodes an HA subtype not normally seen in humans, it is called antigenic shift6,55. As a 
result of antigenic shift, it is possible to generate an animal virus capable of infecting humans. If 
the HA subtype encoded by this reassortant virus has not circulated in humans previously, the 
resulting influenza enters an immunologically naïve population with, by definition, an extremely 
high number of susceptible individuals6. It is in these scenarios that pandemics emerge, such as 
the 2009 H1N1 pandemic, which resulted from progressive reassortment between human, avian, 
North American swine, and Eurasian swine IAVs56. 
 Though it is able to cause severe disease and is responsible for seasonal epidemics 
worldwide like IAV, IBV is not a pandemic threat. This is due to the fact that IBV is capable of 
antigenic drift but not antigenic shift6,7. Antigenic drift describes the steady accumulation of 
mutations in antibody binding sites over time, leading to a progressive loss of preexisting 
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immunity6. This constant level of change observed in both IAV and IBV is what requires the 
production of a new influenza vaccine every season. However unlike IAV, IBV is considered 
monosubtypic7. IBV exists in only two genetically and antigenically divergent lineages, Victoria 
and Yamagata. As a result, it does not possess the subtype diversity and potential for genetic 
reassortment necessary to afford it pandemic potential7,12. It is for this same reason that ICV is 
also not a pandemic threat. Although it exists in six genetically and antigenically distinct 
lineages, ICV is evolutionarily stable and is also monosubtypic1,6,7,12. Therefore, of the original 
three influenza genera, only IAV possesses the subtype diversity and zoonotic hosts necessary to 
impart it with the potential for zoonotic emergence and pandemic spread. 
 As of 2020, four lineages of IDV have been identified based on the sequence of their 
HEF protein. Represented by D/swine/Oklahoma/1334/2011 (D/OK), 
D/bovine/Oklahoma/660/2013 (D/660), D/bovine/Yamagata/10710/2016 (D/Yama2016), and 
D/bovine/Yamagata/1/2019 (D/Yama2019), the four lineages have been found to frequently 
reassort and some of these lineages co-circulate worldwide in both cattle and swine6,53,57. Though 
it is currently unknown whether multiple subtypes of IDV exist, its ability to infect and reassort 
within non-human maintenance hosts may allow the virus to act similarly to IAV. Adding to 
concerns about the virus, genomic analyses of IDVs isolated from a Mississippi cattle facility 
found evidence of antigenic drift along with active virus reassortment in cattle57. In the same 
study, it was shown that IDV seropositive cattle were not protected from experimental 
reinfection, potentially leading to the virus’s widespread dissemination in animal populations57. 
Additionally, the evolutionary rate of IDV is 1.68 x 10-3 nucleotide substitutions per site per year 
in the HEF gene. This is significantly higher than ICV and on par with some subtypes of IAV 
(between 1–8 x 10-3 nucleotide substitutions per site per year of the HA gene), suggesting that 
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IDV is not evolutionarily stable, unlike ICV53. Overall, non-human reservoirs, a wide natural 
host range, multiple reassorting lineages, and high substitution rate suggest that IDV could be of 
pandemic concern.  
Influenza D Virus Infection of Humans 
 Influenza D viruses could pose a public health concern. Several serological surveys have 
been conducted to investigate the extent of IDV spillover into the human population. Serum 
samples collected from 316 individuals 60 years and older in Canada (i.e., Vancouver) and the 
U.S. (i.e., Connecticut) during the 2007-08 and 2008-09 influenza seasons demonstrated a 
seropositivity rate of 1.3%7. This low seroprevalence is in agreement with another study 
investigating 3300 human respiratory samples collected between 2006-08 from Edinburgh, 
Scotland, which detected no IDV by RT-PCR in any sample58. An investigation of occupational 
exposure to cattle in Florida during 2011-12, however, demonstrated a 97% seropositivity rate in 
cattle-exposed individuals versus 18% in non-cattle-exposed persons59. Though the small sample 
size (n=46: 35 cattle-exposed, 11 non-cattle-exposed) of this study should be taken into account, 
these results suggest that occupational zoonotic transmission of IDV may be taking place. A 
serologic study assessing the prevalence of IDV antibodies in the Italian population between 
2005 and 2017 also suggested higher seroprevalence in the human population, though it showed 
an inconsistent increase in antibody titers60. In this study, antibodies to IDV were present in at 
least low levels (5.1% and 9.8%) every year. However, sharp increases (33.9-46.0%) were 
observed in years following epidemics of IDV in cattle and swine60. As a result, these findings 
suggest that spillover from an animal reservoir into the human population can occur but provide 
no evidence for IDV transmission within humans60. In summary, these studies suggest that 
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occupational contact with IDV-infected animals is the most probable route of human infection, 





 Due to its wide host range (e.g., cattle, pigs, and other domesticated animals) and high 
genome mutation rate, there is concern that IDV has the potential to serve as a zoonotic threat to 
humans. Prior to the isolation of IDV, IAV was the only influenza virus to have a non-human 
primary host, large subtype diversity, and pandemic potential7. While bovines are currently 
hypothesized to be the reservoir of IDV, the virus infects a wide range of species and serological 
surveys show the presence of antibodies that recognize IDV in human sera. Together, these 
findings illustrate that IDV can infect humans, but to date there is no evidence of human-to-
human transmission1,58–61. Currently the cellular tropism and disease severity of IDV infection in 
humans are unknown. Additionally, it is unclear if IDV infects respiratory epithelial cells in both 
the upper and lower respiratory tract and to what extent physiological ranges of temperature 
(32˚C and 37˚C) impact cellular preference. In this study, I sought to characterize the ability of 
IDV to infect primary human nasal epithelial cells, determine its cellular tropism, and 
characterize the production of various innate immune factors in virus-infected cells. I also sought 
to determine how physiologically relevant temperature ranges (32˚C and 37˚C) could affect virus 
replication and induced cytokine/chemokine responses. I hypothesize that IDV will show limited 
replication in human nasal epithelial cell cultures and induce limited amounts of cytokines and 





MATERIALS AND METHODS 
Cell Lines 
Madin Darby Canine Kidney (MDCK) cells were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM, Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS, Gibco Life 
Technologies), 100U/mL penicillin with 100µg/mL streptomycin (Quality Biological), and 2mM 
L-glutamine (Gibco Life Technologies) at 37˚C with 5% CO2.  
Human nasal epithelial cell (hNEC) cultures were isolated from the disease-free nasal 
tissue, collected during endoscopic sinus surgery mandated for disease-unrelated conditions. The 
cells were then differentiated at an air-liquid interface (ALI) in 24-well Falcon filter inserts (0.4-
µM pore; 0.33 cm2; Becton Dickinson) at 37˚C with 5% CO2. ALI medium containing 1X ALI 
maintenance supplement (STEMCELL Technologies), 0.192 µg/mL hydrocortisone stock 
solution (STEMCELL Technologies), and 5 IU/mL 0.2% heparin solution (STEMCELL 
Technologies) was used as basolateral medium. 
Viruses 
Swine nasal swabs and nasal wipes were collected as part of the active influenza 
surveillance effort conducted by the Animal Influenza Ecology and Epidemiology Research 
Program at The Ohio State University, Department of Veterinary Preventive Medicine. Samples 
were collected during two agricultural exhibitions (11/5/2017 and 5/26/2018). At the time of 
sampling, none of the swine exhibited clinical signs of disease. In 2017, nasal swabs were 
collected from an agricultural exhibition in Kentucky where both pigs and cattle from multiple 
states across the U.S. were being shown, though the species were housed in different barns. In 
2018, nasal wipes were collected at a swine-exclusive show in Ohio with pigs coming 
exclusively from Ohio. From these samples, researchers at The Ohio State University isolated 
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two viruses, D/swine/Kentucky/17TOSU1262/2017 – which they sequenced (consecutive 
GenBank accession numbers MK054178 to MK054184)62, and 
D/swine/Ohio/18TOSU0287/2018. These two viruses – minimally passaged in MDCK cells – 
were provided to us along with six brain heart infusion broth (i.e., field) samples, two from 2017 
and four from 2018, for attempted viral isolation. An ICV was selected from existing lab stocks 
to act as a comparison virus. Of the available viruses, influenza C/Ann Arbor/1/1950 was 
selected for its ability to replicate to measurable titers on MDCK cells.   
IDV Isolation from Brain Heart Infusion Broth (BHIB) Samples 
In order to isolate IDV virus from BHIB samples, 100% confluent MDCK cells in 3.5 
cm2 dishes were infected with 250µl of each BHIB sample diluted 1:1 in infection media 
(IM+NAT; DMEM, 0.3% Bovine Serum Albumin [BSA, Sigma], 100U/mL penicillin, 
100µg/mL streptomycin, 2mM L-glutamine, and 5µg/mL N-acetyl trypsin [NAT; Sigma, St. 
Louis, MO]). The cells were infected at 37˚C with 5% CO2 for 1 hour rocking every 10 minutes. 
After 1 hour, the inoculum was replaced with 1mL IM+NAT and the progression of cytopathic 
effect (CPE) monitored daily. Virus containing supernatant was collected when 70-90% CPE 
was achieved, approximately 5 days post infection. Infectious viral titer of the supernatant was 
then quantified using TCID50 assays. Any supernatant found to contain virus was used to 
generate seed and working stocks.  
50% Tissue Culture Infectious Dose (TCID50) Assay 
 IDV TCID50 assays were conducted using 96-well plates of 90-100% confluent MDCK 
cells. After the cells were washed twice with PBS+, ten-fold serial dilutions of each virus in IM 
were produced, and 20µL applied to 6 wells of cells. The plates were then incubated at 32˚C with 
5% CO2 for 6 days. The cells were then fixed with 4% formaldehyde in PBS overnight and 
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stained with Napthol Blue Black overnight. The resulting CPE was scored visually and the 
TCID50 value for each sample was calculated using the Reed-Muench calculation
63. 
Seed Stock and Working Stock 
To produce IDV seed stocks, virus inoculum was generated by diluting virus or BHIB 
isolate to a multiplicity of infection (MOI) of 0.001 TCID50 units/cell in IM+NAT. 
Approximately 100% confluent T-150 (150 cm2) flasks of MDCK cells were then washed twice 
with PBS+ (1x phosphate buffered saline [PBS] supplemented with calcium and magnesium) 
and infected with 5mL/flask of inoculum, rocking every 10 minutes for 1 hour at 32˚C with 5% 
CO2. Each flask was then given 20mL of IM+NAT, incubated at 32˚C, and the progression of 
CPE monitored daily. Virus containing supernatant was collected when 70-90% CPE was 
achieved, approximately 4 days post infection. Infectious viral titer of the seed stocks was then 
determined using TCID50 assays. Working stocks were produced in the same fashion using the 
steed stock to generate the viral inoculum.  
Plaque Assay  
 Plaque assays were performed in 6-well plates containing 90-100% confluent MDCK 
cells. The cells were washed twice with PBS+ then infected with 250µl of serial 10-fold dilutions 
of IDV in IM+NAT. The plates were then allowed to incubate at 32˚C with 5% CO2 for 1 hour 
rocking every 10 minutes, after which the inoculum was aspirated and a layer of 1% agarose 
solution was added to each well. The 1% agarose was generated by adding 25mL of 2% agarose 
in water to 25 mL of 2x Modified Eagle Medium (Gibco Life Technologies) supplemented with 
200U penicillin/mL, 200µg streptomycin/mL, 4mM L-glutamine, 0.2M HEPES (Gibco), and 
5μg/mL NAT. After the agarose solidified, the plates were incubated at 32˚C for 4 days, fixed 
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with 4% formaldehyde (Fisher Chemical) in PBS overnight, then stained with Napthol Blue 
Black overnight. 
 To quantify plaque area, the wells and a ruler were imaged using a Nikon Fluorescence 
Dissection Microscope with an Olympus DP-70 color camera. The resulting pictures were 
uploaded to ImageJ (NIH), where the ruler image was used to set the reference scale of 1 cm and 
the Freehand Selector was used to trace the outline of each individual plaque, incorporating all 
cells showing CPE (including grey halos present around clear plaques). Plaque area 
measurements were then calculated by ImageJ and the resulting data transferred to GraphPad 
Prism 8 (GraphPad Software, San Diego, CA) for analysis and graphing. 
Low MOI Growth Curves (GC) 
MDCK 
 MDCK cells were seeded into 24-well plates and allowed to reach 100% confluence. 
After being washed twice with PBS+, the cells were infected with 100µL of virus diluted to a 
MOI of 0.001 in IM+NAT and set on a rocker for 1 hour at room temperature. The inoculum was 
then removed, the cells washed 2 times with PBS+, and 500µL of IM+NAT added to each well. 
The plates were then incubated at 32˚C or 37˚C with 5% CO2 and samples collected at 1, 12, 24, 
36, 48, 72, 96, 120, 144, and 168 hours post infection. 
 hNEC 
Fully differentiated hNECs cultured on transwells in 24-well plates had their basolateral 
media collected and their apical surfaces washed three times by repeating the process of adding 
100µL of IM with no NAT (IM-NAT), incubating for 10 minutes at 32˚C or 37˚C with 5% CO2, 
then aspirating. The cells were then infected by adding 100µL of IDV diluted to a MOI of 0.1 in 
IM-NAT to the apical surface for 2 hours at 32˚C or 37˚C with 5% CO2. Following infection, the 
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cells were washed three times with PBS- (PBS without calcium and magnesium) and then 
incubated at 32˚C or 37˚C with 5% CO2. Apical samples were taken at 1, 12, 24, 36, 48, 72, 96, 
120, 144, and 168 hours post infection by applying 100µL of IM-NAT to the apical surface, 
incubating at 32˚C or 37˚C for 10 minutes, removing the apical wash, and storing at -70˚C. 
Basolateral supernatants were collected and replaced every 48 hours. Infectious viral titer was 
then quantified using TCID50 assays. 
Deconvolution Microscopy of IDV Infection in hNECs 
The cellular tropism of IDV was investigated through the use of deconvolution 
microscopy. The apical surface of differentiated hNEC cultures was washed three times by 
applying IM-NAT, incubating at 32˚C for 10 minutes, then aspirating the media. Fresh ALI was 
then added to the basolateral surface. The viruses were diluted to a MOI of 2 in IM-NAT then 
applied to the cells for 2 hours at 32˚C. Following this incubation period, the cells were washed 
three times with PBS- and were permitted to incubate at 32˚C for 16-18 hours. 
After incubating overnight, the cells were fixed with 4% paraformaldehyde in PBS and 
the semipermeable membrane of the hNEC culture was cut in half. One half of the membrane 
was placed cell-side down in perm buffer (PBS- with 0.2% Triton X-100 [Sigma-Aldrich, St. 
Louis, MO]) followed by blocking buffer (5mL PBS-, 100uL normal goat serum [Sigma, St. 
Louis, MO], and 85uL 30% BSA). For detection of IDV infected cells, the hNECs were then 
incubated with rabbit polyclonal antibodies against swine D/OK IDV (Provided by the Feng Li 
Lab). Ciliated cells were identified using mouse monoclonal anti-tubulin Beta 4 (NBP2-00812, 
Novus Biologicals). Following a wash in wash buffer (PBS- and 0.2% Tween-20 [Sigma, St. 
Louis, MO]), the hNECs were secondarily stained with Alexa Fluor™ 488-labeled goat anti-
rabbit IgG (H + L) (A11034, Life Technologies Corporation) and Alexa Fluor™ 555-labeled 
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goat anti-mouse IgG (H + L) (A21424, Life Technologies Corporation). The immunostained 
cultures were mounted on Superfrost®/Plus microscope slides (Fisherbrand) in ProLong™ Gold 
antifade reagent with DAPI (Invitrogen) and covered with 1oz. Premium Cover Glass (Fisher 
Scientific) coverslips. Z-stack images were then taken on a Zeiss AxioImager M2 microscope 
with attached Hamamatsu Digital Camera C10600 ORCA-R2 using a step size of 0.5μm and the 
40x/0.75 Ph2 objective. Images were deconvolved and cropped using the integrated Volocity 
software. 
Interferon, Cytokine and Chemokine Measurements 
 Interferons, cytokines, and chemokines present in basolateral samples collected at 0, 48, 
96, and 144 hours post infection during low MOI hNEC GCs were measured using the V-PLEX 
Human Chemokine Panel 1 (Eotaxin, MIP-1β, Eotaxin-3, TARC, IP-10, MIP-1α, IL-8, MCP-1, 
MDC, MCP-4) (Meso Scale Discovery) according to the manufacturers’ instructions. 
Statistical Analysis 
 Low MOI GCs were analyzed by mixed ANOVA with repeated measures followed by a 
Tukey’s multiple comparisons test in GraphPad Prism 8. Plaque areas were analyzed by one-way 
ANOVA in GraphPad Prism 8. MSD data was processed in MSD DISCOVERY WORKBENCH 
4.0 then analyzed for significant differences using GraphPad Prism 8 to conduct a mixed 





Virus isolation from Brain Heart Infusion Broth (BHIB) samples 
To reduce the risk of cross contamination between samples, BHIB samples provided by 
The Ohio State University were used to infect MDCK cells in individual 3.5 cm2 dishes. 
Following inoculation, the dishes were monitored daily until 70-90% CPE was achieved. Most 
samples showed this level of CPE in 5 dpi (Figure 1). However, despite anti-bacterial 
supplements in the media, samples 17SW1268 and 18SW0287 showed evidence of bacterial and 
fungal contamination at 2 dpi at which point the dishes were discarded. Infectious viral titer of 
supernatants collected from the remaining dishes at 5 dpi were determined via TCID50 assay. Of 
the four samples that did not show contamination over the course of the experiment, only sample 
17SW1262 had a titer above the assay’s limit of detection (3.41 x 108 TCID50/mL; TCID50 
assay LOD = 2.32 x 102 TCID50/mL). As a result, the virus isolated from sample 17SW1262 
was designated D/swine/Kentucky/17SW1262/2017 (17SW) and was used to generate seed and 
working stocks for use in future experiments. I did not investigate what was causing the CPE in 
the other samples that did not yield infectious virus by TCID50 on MDCK cells.  
IDV plaque assays conducted at 32˚C and 37˚C indicate a temperature sensitivity in the 
2017, but not 2018, viruses 
 In order to evaluate the ability of 17SW, D/swine/Kentucky/17TOSU1262/2017 
(17TOSU), and D/swine/Ohio/18TOSU0287/2018 (18TOSU) to infect and kill neighboring cells 
in a MDCK monolayer at temperatures representative of the upper and lower respiratory tract, 
plaque assays were conducted at 32˚C and 37˚C.  
At 32˚C, all of the viruses generated clear plaques surrounded by a grey halo of dying 
cells (Figure 2B). Halos generated by 18TOSU infection were observed to be smaller than those 
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surrounding areas of clearance in 17TOSU and 17SW infections. Clearance of cells in the 
monolayer is indicative of the virus’s ability to infect and kill cells at this temperature. Despite 
similarities in plaque morphology, variation in plaque area was observed between the three 
IDVs. Though the viruses displayed a wide range of plaque areas, 18TOSU was found to 
produce significantly larger plaques than 17TOSU (Figure 2A). This is evident when comparing 
the average plaque size for all the viruses (17SW: 0.913 ± 0.661 mm2; 17TOSU: 0.824 ± 0578 
mm2; 18TOSU: 1.157 ± 0.741 mm2). This suggests that 18TOSU was more capable of 
replicating and spreading to adjacent cells than 17TOSU, while 17SW was not significantly 
different from either. 
Changing the temperature at which the assay was conducted had a large influence on 
plaque morphology. At 37˚C, only 18TOSU retained its ability to generate clear plaques in the 
MDCK monolayer. Neither 17TOSU nor 17SW were able to kill the cells they infected, resulting 
in diffuse plaques that were difficult to distinguish from the rest of the monolayer (Figure 3B). 
As a result, only plaques generated by 18TOSU were able to be quantified (Figure 3A). Also, the 
area of the plaques resulting from 18TOSU infection was dramatically impacted by temperature. 
Whereas 18TOSU’s average plaque size was 1.079 ± 0.741 mm2 at 32˚C, at 37˚C it was 4.437 ± 
2.883 mm2 (Figure 3A). This data indicates that 18TOSU is able to form clear, distinct plaques at 
both 32˚C and 37˚C, but the ability of 17TOSU and 17SW to form clear plaques was restricted to 
32˚C.  
Infectious viral growth kinetics on MDCK cells at 32˚C demonstrate efficient IDV 
replication in this cell type and temperature 
 The infectious growth kinetics of IDV infection were characterized by conducting multi-
step growth curves on MDCK cells at 32˚C. Peak viral titer (approximately 8-9 LogTCID50/mL) 
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was achieved at 96 hpi for all viruses (Figure 4). After reaching peak titer, 18TOSU replication 
fell significantly below that of 17TOSU and 17SW. Thus, it can be concluded that all three IDV 
strains replicate efficiently at 32˚C, with the 2017 viruses reaching significantly higher titer than 
18TOSU.  
Infectious viral growth kinetics on hNEC cultures at 32˚C and 37˚C illustrate the ability of 
IDV to infect and replicate in a cell culture system representative of the human upper and 
lower respiratory tract 
 The ability of IDV to replicate in a physiologically relevant cell culture system was 
evaluated using multi-step growth curves on differentiated hNEC cultures at 32˚C and 37˚C 
(Figure 5A). At 32˚C, all three IDV strains reached peak viral titer at approximately 72 hpi and 
replicated to statistically significantly higher titers when compared to ICV, C/Ann Arbor/1/1950 
(C/AA; Figure 5B). At 37˚C, 18TOSU and 17TOSU reached peak titer at 48 hpi and replicated 
to equivalently high titers (Figure 5C).  
Though ICV is most closely related to IDV, several issues exist with using C/AA as a 
comparative virus. 17TOSU, 18TOSU, and 17SW are field isolates passaged minimally in cell 
culture so that they retain their natural infective ability. C/AA however is a virus isolated in 1950 
that has been passaged extensively in cell culture, making it heavily cell culture adapted. Due to 
the mild disease presentation of ICV infection, surveillance for this genus of influenza virus is 
uncommon, making finding a field isolate of ICV challenging. For this reason, C/AA was not 
used in the 37˚C analysis of IDV replication. Additionally, 17SW and 17TOSU originated from 
the same field sample. The difference between these viruses is that 17TOSU was isolated and 
sequenced by The Ohio State University, whereas 17SW was isolated as part of this series of 
experiments and has not been sequenced. Due to extensive similarities in plaque morphology and 
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replication on MDCK and hNECs at 32˚C, it was assumed that 17TOSU and 17SW are identical 
and thus 17SW was not included in the 37˚C hNEC low MOI GCs.  
The data demonstrated in Figure 5 indicate that IDV is capable of replicating to high titer 
in human primary nasal epithelial cells at temperatures mimicking the upper and lower 
respiratory tract, suggesting the potential to productively and efficiently infect humans in vivo. 
Additionally, high titer replication of influenza viruses at 37˚C is commonly associated with 
more severe disease. Thus, efficient replication of IDV at this temperature indicates a potential to 
cause disease in humans. 
Deconvolution microscopy of IDV infected hNEC cultures indicates tropism for non-
ciliated cells 
 The cellular tropism of IDV infection was investigated through deconvolution 
microscopy. hNEC cultures were stained to visualize the cellular localization of IDV and β-
tubulin IV. β-tubulin IV is a cytoskeletal constituent of the microtubules present in cilia, 
therefore staining this component allows for the identification of ciliated cells. By carrying out 
deconvolution microscopy that allows several images to be taken in layers and resolved, 
fluorescently labeled objects at different depths within the sample are able to be viewed in focus 
simultaneously. Thus, allowing for visualization of both cilia on the surface of the cell and IDV 
replicating within the nucleus. If the anti-IDV and anti-β-tubulin IV staining overlaps, then it can 
be said that IDV preferentially infects ciliated cells. However, as seen in Figure 6, though all 




MSD analysis of the innate immune response induced by IDV compared to ICV infection of 
hNEC cultures at 32˚C  
All three IDVs and a comparative ICV were used to infect hNEC cultures at 32˚C for up 
to 168 hpi with basolateral supernatants being collected at 0, 48, 96, and 144 hpi. Despite 
C/AA’s heavy cell culture adaptation, infection with ICV is known to cause mild disease, 
making it an effective comparison for this analysis. Expression of 7 of the 10 factors evaluated 
differed between IDV and ICV infections. Of these factors only Eotaxin-3 and IP-10 secretion 
was upregulated, whereas IL-8, MCP-4, MDC, MIP-1α, and TARC expression was 
downregulated during IDV infection. Overall, differences in cytokine induction were consistent 
across all time points with the exception of Eotaxin-3 and IP-10 whose significance emerged at 
later timepoints (Eotaxin-3: 96 and 144 hpi, IP-10: 144 hpi). This consistent downregulation of 
several factors essential for the innate immune response to infection suggests either that IDV has 
a lesser disease presentation than ICV or that IDV has more enhanced immune evasion 




Figure 1. Virus Isolation from BHIB Samples. Individual 3.5 cm2 dishes containing 100% 
confluent MDCK cells were infected with one BHIB sample each and monitored daily for CPE. 
Sample 17SW1268 showed signs of bacterial contamination at 2 dpi, as indicated by clouding in 
the supernatant. Fuzzy particles observed in sample 18SW0287 at 2 dpi suggested fungal 
contamination. As a result, the dishes containing 17SW1268 and 18SW0287 were discarded, 
thus no images of these samples are available for days 3-5 post infection, as is indicated by the 
red Xs. The remaining samples did not show any visible signs of contamination and thus were 
permitted to continue infecting up to 5 dpi at which point the supernatants were collected for 








Figure 2. IDV Plaque Assay at 32˚C. Evaluating the ability of IDV to infect and kill adjacent 
cells in a MDCK monolayer through plaque area and morphology at 32˚C. (A) Plot of individual 
plaque area with lines representing mean and standard deviation. A minimum of 130 plaques 
coalesced from 3 independent experiments, each with 2 biological replicates, were quantified for 
each virus. Data points greater than two standard deviations from the mean were excluded as 
outliers. (B) Representative images of plaque morphology resulting from infection with 17SW, 






Figure 3. IDV Plaque Assay at 37˚C. Evaluating the ability of IDV to infect and kill adjacent 
cells in a MDCK monolayer through plaque area and morphology at 37˚C. (A) Plot of individual 
plaque area with lines representing mean and standard deviation. 97 plaques coalesced from 3 
independent experiments, each with 2 biological replicates, were quantified for 18TOSU. (B) 
Representative images of plaque morphology resulting from infection with 17SW, 18TOSU, and 




Figure 4. 32˚C IDV Low MOI MDCK GC. Multi-step growth curve performed on MDCK 
cells infected with a MOI of 0.01 at 32˚C. Statistical significance was measured using a 
MANOVA with repeated measures followed by a Tukey’s post-test. Results are from 4 
independent experiments, each with 3 biological replicates. ****p<0.0001. Limit of detection 











32C Low MOI MDCK Growth Curve










































Figure 5. Low MOI hNEC GCs conducted at 32˚C and 37˚C demonstrate efficient 
replication of IDV in human cells. hNEC cultures provide an in vivo model representative of 
the human respiratory tract. (A) Image describing the hNEC workflow. Disease free nasal tissue 
collected during elective surgery is cultured at the air-liquid interface on transwell inserts. 
Following differentiation, the cells are acclimated to either 32˚C or 37˚C and then infected with 
the desired viruses. Samples were collected every 12 hours for the first 48 hours, then every 24 
hours until 168 hpi. (B) Multi-step growth curve performed on differentiated hNEC cultures 
infected with a MOI of 0.1 at 32˚C. Results are from 3 independent experiments, each with 3 
biological replicates. (C) Multi-step growth curve performed on differentiated hNEC cultures 
infected with a MOI of 0.1 at 37˚C. Results are from 1 independent experiment with 3 biological 
replicates. Statistical significance was measured using a MANOVA with repeated measures 
followed by a Tukey’s post-test. ****p<0.0001.  L.O.D = 2.37 log TCID50/mL. 
  






37C Low MOI hNEC Growth Curve




















32C Low MOI hNEC Growth Curve























Figure 6. hNEC culture infected with 18TOSU imaged through deconvolution 
microscopy. These images were taken by a Zeiss AxioImager M2 microscope with attached 
Hamaumatsu camera. Anti-β-tubulin IV in the 555 channel fluoresces red, indicating the 
presence of cilia. Anti-C/OK in the 488 channel fluoresces green, indicating the presence of 
virus. Co-localization of β-tubulin and IDV was used as a qualitative evaluation of cellular 
tropism. Despite the cultures containing predominantly ciliated cells, indicated by the pervasive 
red staining, IDV was observed to infect a very limited number of cells. This suggests that the 



































Figure 7. MSD analysis of the innate immune response to IDV infection at 32˚C. Basolateral 
supernatants collected at 0, 48, 96, and 144 hpi over the course of 32˚C low MOI hNEC GCs 
(Figure 5B) were evaluated via MSD assay. Results are from 3 independent experiments, each 
with 3 biological replicates. (A-D) Radar graphs illustrating fold change in cytokine expression 
induced by IDV infection compared to ICV infection. The Y-axis represents a logarithmic scale, 
therefore a value of 1 indicates no difference between 17TOSU, 17SW, or 18TOSU and C/AA. 
Values greater or lower than one indicates a difference from ICV. *= any significant difference 
between an IDV virus compared to C/Ann Arbor/1/1950. (A) MSD analysis of basolateral 
supernatants collected at the time of infection. (B) MSD analysis of basolateral supernatants 
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collected 48 hpi. (C) MSD analysis of basolateral supernatants collected 96 hpi. (D) MSD 
analysis of basolateral supernatants collected 144 hpi. (E-H) Tables detailing the level of 
significant difference between all three IDV viruses and C/AA for each timepoint post infection. 
Color indicates directionality of difference; blue indicates downregulation in comparison to 
C/AA and green indicates upregulation in comparison to C/AA. Statistical significance was 
measured using a MANOVA with repeated measures followed by a Tukey’s post-test. *p<0.05, 





Following the isolation of IDV in 2011, few studies have been conducted evaluating its 
potential as a human pathogen. Unlike its closest genetic relative ICV, IDV is neither exclusively 
a human pathogen nor evolutionarily stable. Instead, IDV possesses a bovine natural reservoir, a 
wide host range, multiple reassorting lineages, and a high substitution rate, all of which are more 
reminiscent of IAV, a virus known for zoonotic spillover and pandemic potential. These 
characteristics may cause IDV to be a threat to public health. Despite this evidence supporting 
the potential of IDV to infect humans, significant disease resulting from IDV infection has yet to 
be reported. In this study we sought to evaluate the zoonotic potential of IDV by evaluating its 
ability to replicate at physiologically relevant temperatures, investigating its cellular tropism, and 
measuring the innate immune response to infection as a proxy for disease presentation. Though 
we anticipated low levels of replication at 32˚C and 37˚C, we demonstrated that IDV readily 
infects and replicates to high titer at both temperatures in fully differentiated hNEC cultures. 
Additionally, we found significant differences in the cytokine and chemokine profiles induced by 
IDV versus ICV infection. Together, these results indicate that IDV is capable of replicating in 
the human nasal epithelial cells and may be capable of inducing disease. Therefore, we can 
conclude that IDV has the potential to pose a zoonotic threat to humans warranting further 
investigation. 
Given that there are no reports of respiratory disease in humans caused by IDV infection, 
my results are surprising. Based on the robust replication observed in hNEC cultures, I would 
expect that both respiratory disease and transmission is possible in humans. This data suggests 
that increased surveillance for IDV in human populations – particularly humans in close contact 
with livestock – is warranted in order to determine the true disease potential of IDV infection.  
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While significant changes in cytokine and chemokine production were detected in IDV 
versus ICV infected hNEC cultures, the induction of most factors was decreased during IDV 
infection. This suggests that IDV either does not induce robust chemokine responses and 
therefore induces less immune mediated disease, or IDV possesses a very strong ability to inhibit 
host responses to infection. Given the significantly greater infectious virus production of IDV 
when compared to ICV in hNEC cultures, this reduced chemokine production was surprising. 
Typically, cytokine and chemokine induction in hNEC cultures is directly proportional to virus 
production, suggesting that the interaction of IDV with human nasal epithelial cells is 
considerably different when compared to ICV64,65.  
It is possible that severe disease after IDV infection in humans requires the presence of 
other respiratory pathogens, as seen in BRD. The lack of similar co-pathogens in humans may 
explain the lack of severe disease but our data on infectious virus titers produced in hNEC 
cultures would suggest prolonged virus shedding in humans is possible. Environmental factors 
such as temperature and humidity may be important barriers to IDV transmission in ways that 
are unique from IAV, IBV, and ICV. 
MDCK cells are the gold standard for influenza virus isolation and propagation due to 
their surface expression of α2,6-sialic acid, α2,3-siaic acid, and Neu5,9Ac2, making them 
susceptible to infection by all genera of influenza66,67. However, the in vivo implications of 
results obtained using this immortalized cell line are limited. In contrast, hNEC cultures derived 
from disease free nasal tissue act as an in vitro surrogate model of the human respiratory tract, 
thus imbuing findings using these cells with greater clinical significance. As a result, we started 
our characterization of IDV growth kinetics on MDCK cells and used the outcomes to drive 
experiments in primary cell culture. In MDCKs, we found that IDV replicates to high titer at 
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32˚C. These results were mirrored in hNECs, where replication to high titer at 32˚C suggests 
IDV is able to actively infect the human upper respiratory tract, a finding widely supported by 
prior literature identifying IDV infection in the upper respiratory tract of pigs and cattle7,11–13,17. 
However, unlike past research suggesting that IDV titers decreased moving lower in the 
respiratory tract of cattle6,17, low MOI hNEC GCs conducted at 37˚C revealed high titer 
replication, indicating that IDV has the potential to infect the lower respiratory tract and 
therefore may be capable of causing severe disease. These results are consistent with another in 
vitro study demonstrating efficient replication of IDV on primary cells at 37˚C68. 
Plaque assay analysis of the three IDV strains used in this study showed evidence of a 
temperature attenuation present in the 2017 viruses compared to the 2018 virus. Both 17SW and 
17TOSU displayed vast changes in plaque morphology between 32˚C and 37˚C, becoming 
incapable of killing cells in an MDCK monolayer at higher temperature. In contrast, 18TOSU 
showed increased replication at 37˚C, as indicated by the larger plaque area, and maintained its 
ability to kill the cells it infected. This suggests that 18TOSU may possess enhanced replication 
in the lower respiratory tract as compared to 17SW and 17TOSU. However, when replication of 
the IDV strains was compared on hNEC cultures, 18TOSU did not demonstrate enhanced 
infection ability at 37˚C. This discrepancy in results is likely due to differences in cell type, in 
which the replication advantage of 18TOSU at 37˚C is present in MDCK cells but is not apparent 
in hNECs, suggesting that the temperature attenuation observed in the 2017 viruses on MDCKs 
would not hinder their ability to replicate in the lower respiratory tract in vivo.  
Deconvolution microscopy qualitatively demonstrated that IDV does not preferentially 
infect ciliated cells. This is in disagreement with a previous study suggesting IDV shared ICV’s 
tropism for ciliated cells68. Quantitative analysis, potentially by flow cytometry, is necessary to 
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definitively determine the cellular preference of IDV infection. Infections at higher MOIs and 
assessing cell tropism at later times post infection, for example at times of maximum infectious 
virus production, may also help clarify which cell types are primarily infected by IDV. 
In summary, we demonstrated that IDV has the potential to efficiently infect and replicate 
within the upper and lower respiratory tract of humans. Due to its bovine natural reservoir, wide 
host range, multiple reassorting lineages, and high substitution rate, the ability of IDV to infect a 
primary cell culture system representative of the human respiratory tract could predict future 
zoonotic spillover and pandemic potential. As a result, our findings suggest that IDV warrants 
further investigation as a potential zoonotic pathogen and indicate that surveillance for this genus 





 Though this study evaluated the replication kinetics of three IDV strains on MDCKs and 
hNEC cultures at 32˚C and 37˚C, additional experiments are needed to fully understand the 
influence of temperature on IDV infection. We failed to completely elucidate the cellular tropism 
of IDV infection. Therefore, deconvolution microscopy conducted either on hNEC cultures 
infected at higher MOIs or at later timepoints during maximum infectious virus production must 
be conducted. Alternatively, flow cytometry evaluating markers for all four cell types found in 
differentiated hNEC cultures and IDV could be carried out in order fully elucidate the cellular 
preference of IDV. 
 Additionally, our results demonstrated that cytokine and chemokine induction was 
significantly reduced during IDV infection compared to ICV infection. These findings can either 
be interpreted as IDV infection does not induce a robust innate immune response or that IDV is 
capable of inhibiting the production of chemokines in virus infected cells. Further studies 
clarifying this distinction will be important to determining if IDV is of lesser or greater zoonotic 
concern.  
 High viral titers achieved during IDV infection of hNEC cultures suggest severe disease 
and prolonged transmission in humans is possible, making the lack of reported infection in 
humans surprising. One potential explanation for this is that environmental factors not 
considered in our evaluation are essential to IDV transmission. Therefore, research investigating 
the impact of variables such as temperature and humidity on transmission must be carried out. 
Finally, our results suggest that humans are susceptible to infection with IDV. A 
serological survey of sera from patients at Johns Hopkins Hospital could be carried out to 
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evaluate the presence of preexisting immunity to IDV in a non-cattle or swine exposed 
population to evaluate current risk of infection. 
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Appendix 1: SARS-CoV-2 Neutralizing Antibody Assays 
INTRODUCTION 
 In December of 2019, SARS-CoV-2 emerged and quickly became a global pandemic. As 
a result, schools and research shut down across the globe. The Johns Hopkins Bloomberg School 
of Public Health was no exception. During this time, all non-SARS-CoV-2 related work was 
halted, including my thesis research on IDV. As our laboratory shifted to COVID-19 related 
research, I altered the focus of my work toward understanding antibody responses to SARS-
CoV-2 infection by conducting neutralizing antibody (nAb) assays developed by our lab.  
During primary infection with a virus or as a result of vaccination, virus-specific B cells 
are generated that produce anti-viral antibodies, most of which recognize the immunodominant S 
protein69. A proportion of these antibodies, particularly those specific for the RBD, are termed 
neutralizing antibodies (nAb)69,70. Through binding to the RBD, nAbs are able to block S protein 
interaction with the cellular receptor for SARS-CoV-2, angiotensin-converting enzyme II 
(ACE2)71, rendering the virus incapable of attaching to target cells and thus preventing fusion 
with the cell membrane69. As a result, nAbs are considered the best correlate of protection 
against SARS-CoV-2 infection following natural infection or vaccination 69,72,73. Therefore, 
research evaluating the presence and function of neutralizing antibodies is of critical importance. 
My contribution to the prodigious body of work surrounding SARS-CoV-2 has been to conduct 
nAb assays as part of larger projects outside of my lab answering a variety of different questions. 
Here I list the publications to which I have made a major contribution and detail my role in each. 
This is not an exhaustive list and only includes articles that have been published or are in 





Benner et al. (2020). SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and 
Convalescent Plasma Donors. The Journal of Infectious Diseases. 
https://doi.org/10.1093/infdis/jiaa581 74 
 In this study, Benner et al.74 strove to determine whether SARS-CoV-2-specific IgG titer 
and avidity are associated with neutralizing antibody titer. To accomplish this, plasma samples 
from 130 convalescent plasma donors and 16 hospitalized patients were used to conduct anti-
SARS-CoV-2 S1- and N-specific IgG ELISAs, avidity assays, and nAb assays. The nAb assays I 
conducted acted as the gold standard to which the ELISA and avidity data were compared. 
Therefore, my work contributed significantly to the author’s determination that anti-S and anti-N 
titers, in addition to anti-S avidity, but not anti-N avidity, are correlated to nAb titer. This led to 
the conclusion that avidity may be used in conjunction with other serologic testing to identify 








Bloch et al. (2021). ABO blood group and SARS-CoV-2 antibody response among 
convalescent plasma donors. Vox Sanguinis. https://doi.org/10.1111/vox.13070 75 
 In this paper, Blotch et al.75 sought to determine the effects of ABO blood group on risk 
of SARS-CoV-2 infection and severity of COVID-19. In order to accomplish this, IgG and IgA 
were measured using the Euroimmun anti-SARS-COV-2 ELISA and nAb titers were measured 
using nAb assay for each of the ABO blood groups. By implementing my nAb assay data, the 
authors determined that nAb titers differed significantly by ABO group, individuals with blood 
group B possessed the highest nAb titers, followed by individuals with A, O and finally AB 
blood groups. This is in contrast to anti-S IgG or IgA which did not differ by blood group. 
Additionally, it was determined that significantly more individuals with blood group B had high 
nAb titers in comparison to blood group O. Therefore, my work contributed heavily to the 
conclusion that an individual’s ABO blood group plays a role in susceptibility to SARS-CoV-2 




PubMed Hyperlink: https://pubmed.ncbi.nlm.nih.gov/33493365/  
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Heaney et al. (2021) Comparative performance of multiplex salivary and commercially 
available serologic assays to detect SARS-CoV-2 IgG and neutralization titers. MedRxiv. 
https://doi.org/10.1101/2021.01.28.21250717 76 
Collection of oral fluid for the detection of SARS-CoV-2 antibodies provides a non-invasive 
means of determining seropositivity. However, research comparing the performance of salivary 
tests with serologic and nAb assays is scarce. To address this, Heaney et al.76 used paired saliva 
and plasma samples from 101 COVID-19 convalescent plasma donors to compare the ability of a 
multiplex salivary SARS-CoV-2 IgG assay recognizing antibodies to N, RBD, and S antigens to 
three enzyme immunoassays and nAb assays. By calculating positive (PPA) and negative percent 
agreement (NPA), overall percent agreement, and Cohen’s kappa coefficient, the authors were 
able to evaluate the concordance between the assays. In comparison to the nAb assay, the PPA of 
the multiplex salivary assay ranged from 62.3% (N) to 96.6% (S) and the NPA varied between 
18.8% (RBD) to 96.9% (S). Through conducting the nAb assays, I contributed to the author’s 
conclusion that the multiplex salivary SARS-CoV-2 IgG assay performed comparably to 
commercially-available enzyme immunoassays and nAbs, suggesting that salivary tests could be 
used to screen the COVID-19 convalescent plasma donor pool, evaluate seroprevalence in the 




PubMed Hyperlink: https://pubmed.ncbi.nlm.nih.gov/33532806/  
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Kared et al. (2021). SARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19 
individuals. The Journal of Clinical Investigation. 10.1172/JCI14547677 
 Though nAb titer is thought to be the best correlate of protection against SARS-CoV-2 
infection, studies have shown that individuals with low or undetectable nAb titers have been able 
to clear the virus78, suggesting a greater characterization of the cellular immune response is 
warranted. Kared et al.77 sought to elucidate the CD8+ T cell response in 30 SARS-CoV-2 
convalescent individuals by using a multiplexed peptide-MHC tetramer approach to screen the 
full SARS-CoV-2 proteome. Using this approach, 408 SARS-CoV-2 candidate epitopes for 
CD8+ T cell recognition were identified allowing for identification and phenotypic 
characterization of virus-specific T cells ex vivo. When comparing expression of markers on 
SARS-CoV-2-specific T cells, consistent with T cell differentiation, to neutralizing antibody 
activity, a correlation was found suggesting higher marker expression was associated with 
stronger nAb activity. Thus, my nAb assays contributed to the author’s conclusion that an 
effective nAb response following SARS-CoV-2 infection is associated with progressive 




PubMed Hyperlink: https://pubmed.ncbi.nlm.nih.gov/33427749/  
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Klein et al. (2020). Sex, age, and hospitalization drive antibody responses in a COVID-19 
convalescent plasma donor population. The Journal of Clinical Investigation.69 
COVID-19 CP therapy has been approved as a treatment for SARS-CoV-2 infection 
under the FDA’s EUA79. However, titers of nAbs have been found to vary widely per individual, 
thus making some individuals better donors than others. In this study, Klein et al.69 sought to 
identify characteristics associated with high nAb titers that would allow for the identification of 
preferred convalescent plasma donors. Age, sex, history of hospitalization for COVID-19, and 
time from infection to plasma collection were evaluated to determine their impact on different 
antibody responses via ELISA assays for anti-S protein domain S1-IgG, anti-S-IgG, and anti-S-
RBD, in addition to nAb assays. Considering the nAb assay results alone, male sex, older age, 
and hospitalization for COVID-19 were indicative of a greater nAb response, whereas days since 
confirmation of infection was negatively associated with nAb area under the curve. In terms of 
effect size, hospitalization was found to be the most highly associated with the generation of 
nAbs. Therefore, by conducting nAb assays, I contributed to the conclusion that age, sex, and 
hospitalization status can be used to screen the CP donor pool for individuals that are most likely 




PubMed Hyperlink: https://pubmed.ncbi.nlm.nih.gov/32764200/   
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Morgenlander et al. (2021). Antibody responses to endemic coronaviruses modulate 
COVID-19 convalescent plasma functionality. The Journal of Clinical Investigation. 
10.1172/JCI14692780 
 Prior exposure to coronaviruses other than SARS-CoV-2 has been predicted to impact CP 
therapy effectiveness81. In this article, Morgenlander et al.81 sought to evaluate the functionality 
of convalescent plasma and screen its reactivity across the genomes of SARS-CoV-2 and four 
endemic human coronaviruses. Functionality was defined as virus neutralization, antibody 
dependent cellular phagocytosis (ADCP), antibody dependent cellular cytotoxicity (ADCC), and 
antibody dependent complement deposition (ADCD) and an algorithm was used to deconvolve 
cross-reactivity between peptides. The nAb titer (NT), ADCP, ADCC, and ADCD of CP from 
126 donors was evaluated and the cohort was divided into high, medium, and low NT groups. 
VirScan was then used to assess peptide epitopes targeted by each of the 126 samples across the 
genomes of SARS-CoV-2, all 4 HCoVs, SARS-CoV-1, MERS, and 3 bat-CoVs. Through the use 
of nAb assays, the authors were able to conclude that high polyclonality of SARS-CoV-2 
antibodies was a predictor of high nAb titer and that high NT plasma and low NT plasma 
recognized mostly the same immunodominant epitopes, though high NT plasma did so at a 
higher frequency. Also, NT, ADCC, ADCP, and ADCD were found to be correlated, though 
individual epitopes had variable associations with the different functionalities. For example, 
antibodies that recognized the immunodominant RBD, fusion peptide, and S1/S2 cleavage site 
peptides were most likely to neutralize SARS-CoV-2, regardless of whether they were generated 
by SARS-CoV-2 or HCoV infection. Thus, my nAb assays contributed significantly to the 
conclusion that prior exposure to HCoVs likely impacts the antibody response to SARS-CoV-2 




PubMed Link: https://pubmed.ncbi.nlm.nih.gov/33571169/  
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Ogega et al. (2021). Durable SARS-CoV02 B cell immunity after mild or severe disease. 
The Journal of Clinical Investigation. https://doi.org/10.1172/JCI14551682 
 One of the primary concerns following infection with or vaccination against SARS-CoV-
2 is the potential for wanning immunity. Time dependent loss of SARS-CoV-2-sepcific 
antibodies could allow for reinfection or infection post-vaccination. To investigate the durability 
of the humoral immune response to SARS-CoV-2, Ogega et al.82 performed multi-dimensional 
flow cytometric analyses of S-RBD-specific memory B cells (MBC) from patients with mild, 
moderate, and severe COVID-19 at approximately 54 days post symptom onset. nAb assays 
were conducted as part of this study to evaluate the possibility of waning nAb titers indicating a 
waning humoral response. By conducting the nAb assays, I helped in the determination that low 
nAb titers are not correlated with detection of S-RBD-specific class-switched MBC. 
Additionally, the publication concludes that S-RBD-specific non-class-switched B cells, S-RBD-
specific class-switched antibody secreting cells, and/or S-RBD-specific class-switched MBC 
were detected in all the individuals studied, independent of nAb titer and severity of disease. 
These results allowed the authors to conclude that most SARS-CoV-2 infected people, even 
individuals with mild disease or low nAb titers, generate S-RBD-specific class-switched MBC, 




PubMed Link: https://pubmed.ncbi.nlm.nih.gov/33571162/   
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Patel et al. (2021). Comparative performance of five commercially available serologic 
assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing 
titers. The Journal of Clinical Microbiology. DOI: 10.1128/JCM.02257-2083 
 Over the course of the pandemic several laboratory tests have arisen to detect anti-SARS-
CoV-2 antibodies. In this study, Patel et al.83 sought to evaluate the ability of five commercially 
available enzyme immunoassays (EIAs) to detect IgG or total anti-SARS-CoV-2 antibodies and 
nAbs. To do this, CP from 140 individuals were evaluating by all five EIAs and nAb assay. By 
comparing the EIAs to nAb assays, the authors determined that there was extensive variation in 
the EIAs ability to differentiate between low and high nAb titers in CP. As a result, my work 
contributed to the conclusion that discretion must be exercised when choosing which commercial 




PubMed Link: https://pubmed.ncbi.nlm.nih.gov/33139419/   
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Appendix 2: D614G Mutation of SARS-CoV-2 
INTRODUCTION 
On December 29, 2019, four patients presenting with pneumonia of unknown etiology 
were admitted to a hospital in Wuhan, Hubei Province, China 84. Epidemiologic investigation 
revealed that the cases were associated with the Hunan Seafood Wholesale Market 84,85. Due to 
the market’s array of meats and live animals, a zoonotic source of the pathogen was suspected 
84,86. Additional cases reported on December 31st linked to the same market strengthened these 
suspicions 87. However, subsequent epidemiological investigation into the increasing number of 
cases demonstrated that only 2% of patients interacted with wildlife directly, whereas over 75% 
were residents, visitors, or contacts associated with Wuhan88,89. This suggested potential human-
to-human transmission88,89. Within a week of the first cases being reported, the etiologic agent of 
coronavirus disease 2019 (COVID-19) was isolated and determined to be a novel coronavirus, 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 85,90. By the 13th of January the 
first case outside of China occurred, opening the floodgates for an outpouring of international 
spread effecting countries in all six WHO regions 87,91. On March 11th, 2020 the WHO officially 
declared the SARS-CoV-2 outbreak a global pandemic 92. One year after the original four cases 
were reported, SARS-CoV-2 is now responsible for 128,540,982 confirmed cases and 2,808,308 
deaths globally (as of March 31st, 2021)93.  
Introduction to SARS-CoV-2 
 SARS-CoV-2 is a non-segmented, positive sense, single-stranded RNA virus belonging 
to the Betacoronavirus genus within the Coronavirinae subfamily of the family Coronaviridae 
89,94. Within the Coronavirinae subfamily there are four genera, Alphacoronaviruses and 
Betacoronaviruses, which primarily infect mammals, and Gammacoronaviruses and 
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Deltacoronaviruses, which primarily infect birds 95. Only seven coronaviruses have been known 
to infect humans, two are Alphacoronaviruses, HCoV-NL63 and HCoV-229E, and the remaining 
five are Betacoronaviruses, including HCoV-OC43, HCoV-HKU1, SARS-CoV, MERS-CoV, 
and SARS-CoV-2 89. Of these Betacoronaviruses, only SARS-CoV, MERS-CoV, and SARS-
CoV-2 are capable of inducing fatal disease 96,97.  
Lifecycle of SARS-CoV-2 
 The genome of SARS-CoV-2 encodes 6 open reading frames (ORFs) that generate 16 
nonstructural proteins which comprise the replicase complex, 9 accessory proteins, and four 
structural proteins which include spike (S), envelope, membrane, and nucleocapsid98–101. Of 
these proteins, S mediates cellular entry, however it is initially generated in an inactive form. In 
order to be capable of mediating fusion, S must be proteolytically cleaved at the S1/S2 polybasic 
cleavage site into its subunits, S1 and S298,100,101. Once cleaved by cellular or viral proteases, the 
S protein becomes fusogenic and its subunits take on unique functions. The S1 fragment 
possesses the receptor binding domain (RBD) which it uses to recognize and bind to the receptor, 
angiotensin-converting enzyme II (ACE2), on the surface of a susceptible cell100,101. Following 
interaction with ACE2, the virus is taken up into the cell within an endosome98. There the S2 
fragment is cleaved again into S2’, exposing a hydrophobic fusion peptide that mediates fusion 
between the viral envelope and the endosomal membrane98,100,101. Fusion between the 
membranes allows the viral genome to be released into the cytoplasm of the cell98. Due to the 
fact that the viral genome is a 5’-capped, positive sense RNA molecule it can be translated 
immediately into protein upon entry99. The first ORFs to be translated are ORF1a and 1b 
resulting in a polyprotein that is cleaved by a viral protease into individual proteins, some of 
which comprise the RNA-dependent RNA polymerase (RdRp) complex responsible for 
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replicating the viral genome. Once assembled, the RdRp reforms the endoplasmic reticulum into 
double-membrane vesicles which are used as factories for replication of the genome and 
generation of subgenomic RNAs which code for the viral structural and accessory proteins98,101. 
Following translation, the structural proteins are inserted into the endoplasmic reticulum-Golgi 
intermediate compartment where virion assembly takes place. The newly produced virions are 
then released at the plasma membrane via exocytosis98,101. 
Origin and Phylogenetic Characterization of SARS-CoV-2 
Prior to the SARS-CoV-2 pandemic, SARS-CoV and MERS-CoV were the only known 
highly pathogenic coronaviruses. Though marked by higher case numbers and lower mortality, 
SARS-CoV-2 shows similarities in its path to emergence. From 2002 to 2003, SARS-CoV 
caused 8096 cases and 774 deaths (CFR = 9.6%), impacting 33 countries across the globe 102. 
Serological analysis of pandemic SARS-CoV isolates demonstrated a 87-92% sequence identity 
to bat SARS-CoV, suggesting bats were the natural reservoir of the virus103. In addition, civet 
cats and raccoon dogs have been implicated as intermediate hosts during the SARS-CoV 
outbreak due to similarities in viral sequences infecting these species97,104. Middle East 
respiratory syndrome coronavirus (MERS-CoV) caused 2229 cases across 27 countries resulting 
in 791 deaths (CFR = 35.5%) between 2012 and 2018105. Similar to SARS-CoV, MERS-CoV 
has been shown to originate in bats and use an intermediate host, dromedary camels, for spillover 
into the human population106. 
In comparison to these highly pathogenic coronaviruses, the symptoms associated with 
SARS-CoV-2 are milder and its transmission between humans is more efficient. As a result, 
SARS-CoV-2 has caused tens of millions of cases but has a mortality rate of approximately 
3.4%97. Phylogenetically, SARS-CoV-2 shares only ~80% sequence identity with SARS-CoV 
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and ~50% with MERS-CoV 107. However, similar to the pattern of emergence seen in SARS-
CoV and MERS-CoV, several studies have demonstrated that SARS-CoV-2 shares high 
sequence identity with bat coronaviruses, suggesting that bats are the probable species of origin 
71,89,107–110. Though bats are considered the source of the outbreak, at the time of the pandemic 
bats were hibernating and no bats were sold at the Hunan Seafood Wholesale Market, suggesting 
an intermediate host would be necessary to initiate human transmission 86. Multiple studies have 
shown high sequence similarity (85.5-92.4%) between SARS-CoV-2 and Pangolin-CoV, 
suggesting that pangolins are a natural reservoir and potential intermediate host for SARS-CoV-
289,109,111,112. 
Cellular Tropism of SARS-CoV-2 
 SARS-CoV-2’s broad cellular tropism may be responsible for the discrepancy between 
its prodigious case numbers and the comparatively smaller impact of SARS-CoV and MERS-
CoV 98. SARS-CoV-2 and SARS-CoV share the same functional receptor, angiotensin-
converting enzyme II (ACE2)71. Important to the evolution of SARS-CoV-2, Zhou et al. 
demonstrated that the virus is able to use ACE2 from Chinese horseshoe bats, civets, and pigs for 
entry into cells71. However, alterations within the RBD of the SARS-CoV-2 S protein permit it to 
make additional contacts with ACE2, allowing it to bind with 10 times greater strength than 
SARS-CoV 113,114. In addition, SARS-CoV-2 possesses a unique furin cleavage site, a RRAR 
insertion at the S1/S2 cleavage site in the S protein98. This may increase the virus’s infectivity by 
making the S protein more susceptible to cleavage into its fusogenic form98. One cellular 
protease in particular has been shown to be responsible for coronavirus S protein priming, 
transmembrane protease serine 2 (TMPRSS2), though infection of cells lacking TMPRSS2 can 
be achieved in the presence of another cellular enzyme, cathepsin L 115. However, due to SARS-
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CoV-2’s unique RRAR insertion, S can be precleaved into S1/S2 by furin, thus reducing the 
virus’s dependence on cellular proteases and enhancing its fusogenic capabilities98,114. This 
enhanced affinity for ACE2 and enzyme promiscuity at the S1/S2 cleavage site are thought to 
contribute to the broad cellular tropism of SARS-CoV-2. 
Upon entry into the respiratory tract, cellular susceptibility to SARS-CoV-2 infection is 
driven by the presence of ACE2 on host cells. Though ACE2 mRNA is present in nearly all 
organs, protein expression is predominantly localized to airway and alveolar epithelial cells, 
vascular endothelial cells, and alveolar macrophages 116. Unlike SARS-CoV, SARS-COV-2’s 
increased affinity for ACE2 allows it to establish infection in the nasal and oral tissues of the 
upper respiratory tract, including nasopharyngeal and oropharyngeal tissues98. Outside of the 
respiratory tract, ACE2 is also expressed on enterocytes in the small intestine116. As a result, 
SARS-CoV-2 is thought to be capable of establishing infection in both the upper and lower 
respiratory tract as well as the gastrointestinal tract98. 
COVID-19 Disease Presentation 
 SARS-CoV-2’s tropism for cells of the respiratory and gastrointestinal tracts is evident in 
its disease presentation. The clinical implications of SARS-CoV-2 infection range from 
asymptomatic to severe influenza-like illness that may progress to respiratory failure and 
death71,98. According to the CDC, the most common symptoms associated with COVID-19 are 
fever or chills, cough, shortness of breath, difficulty breathing, fatigue, muscle or body aches, 
headache, loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and 
diarrhea117. In addition, risk factors for severe disease include age, preexisting conditions 




Transmission of SARS-CoV-2 
 SARS-CoV-2’s tissue tropism and disease presentation directly correlate to its mode of 
transmission. Virus replication in the upper and lower respiratory tracts in addition to frequent 
coughing enables SARS-CoV-2 to be spread through respiratory droplets, contact (direct and 
close), fomites (indirect contact), and aerosols (airborne transmission) (Figure 1)92,98. As 
indicated by the width of the arrows in Figure 1, respiratory droplets are thought to be the 
predominant mode of transmission used by SARS-CoV-298. Virus laced respiratory droplets, 
saliva, and other respiratory secretions are disseminated by symptomatic and asymptomatic 
individuals during normal speech, singing, sneezing, or coughing98,121–124. When susceptible 
individuals come into close or direct contact with an infected individual, these infectious 
secretions may interact with their mouth, nose, or eyes resulting in transmission124. Alternatively, 
these secretions or droplets can settle out of the air, contaminating objects and surfaces resulting 
in the generation of fomites98,124. These fomites are then able to contribute to transmission via 
indirect contact when naïve hosts interact with them then touch their eyes, nose, or mouth98,124. 
Airborne transmission via aerosols has also been reported during small, droplet nuclei generating 
medical procedures and may contribute to transmission in ventilation-poor indoor settings124. 
SARS-CoV-2’s ability to infect cells of the gastrointestinal tract also suggests that fecal-oral 
transmission may be a plausible transmission route. Though no instances of fecal-oral 






Figure 1. Proposed modes of transmission for SARS-CoV-2. Image from Harrison et al. 
(2020)98 depicting proposed transmission routes for SARS-CoV-2. Solid arrow width indicates 
the relative contribution of each transmission route to viral spread. Dashed lines denote plausible 
transmission routes that had yet to be confirmed at the time of publication (December 2020). 
 
Mutations in SARS-CoV02 
Relative to DNA viruses, RNA viruses possess vastly higher rates of mutation. This is 
because the virus-encoded RNA dependent RNA polymerases responsible for replicating RNA 
virus genomes lack exonuclease proofreading ability 128. As a result, whereas DNA viruses have 
between 10-8 to 10-6 substitutions per nucleotide site per cell infection (s/n/c), RNA viruses have 
10-6 to 10-4 s/n/c 129. What makes coronaviruses unique among the RNA viruses is that one of 
their proteins, nsp14, possesses a 3’-5’ exonuclease (ExoN) 130. By combining their functions, 
ExoN is able to remove mutagenic nucleotides erroneously inserted by the low fidelity RNA 
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polymerase resulting in faithful replication of the coronavirus genome and a lower mutation 
rate97,130. 
Though SARS-CoV-2’s rate of mutation is decreased relative to other RNA viruses, the 
sheer number of hosts the virus is passing through combined with the number of replications it is 
undergoing in each individual vastly increases the likelihood of mutations occurring in the viral 
population 70. In addition, as more individuals become infected and recover or become 
vaccinated, selective pressure favoring viral variants that escape naturally or vaccine induced 
immunity increases dramatically 131,132. Therefore, as the pandemic progresses there is increasing 
concern that mutations will occur in epitopes recognized by the neutralizing antibodies 
responsible for conferring protection against SARS-CoV-2. 
D614G Variant 
One mutant that validated concerns of SARS-CoV-2 adaptation to human hosts is the 
Spike protein D614G variant. First identified by Korber et al.70, D614G emerged in Europe and 
accounted for 10% of global sequences prior to March 1st. By May 18th, it represented 78% of 
sequences and had become the dominant strain infecting individuals in Europe, North America, 
Oceania, and Asia70. As the pandemic progresses, the D614G variant continues to represent an 
increasing proportion of sequences worldwide133.  
The D614G mutation occurs in the C-terminal region of the S1 domain of one protomer 
where it associates with the S2 domain of another protomer 134. By replacing aspartic acid with 
glycine at residue 614, hydrogen bonding between protomers of the trimeric spike is disrupted, 
resulting in greater flexibility and altered interprotomer interactions70. Therefore, the protomers 
of the G614 S protein more easily transition from closed conformation, in which the RBD is 
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As the SARS-CoV-2 pandemic progresses, the likelihood of mutant viruses arising that 
evade preexisting immunity or become better suited to infecting humans is high70. One mutation 
that has swiftly arisen and become dominant in viral populations worldwide is D614G70. By 
replacing aspartic acid with glycine at this residue, interprotomer interactions within the trimeric 
spike of SARS-CoV-2 are disrupted, potentially allowing Spike proteins with G614 to have 
increased availability for binding to ACE2133. In this study, we sought to characterize differences 
in viral fitness induced by the D614G mutation by comparing the replication kinetics of D614 
and G614 viruses in a primary human nasal epithelial cell culture system. We hypothesized that 
G614 viruses would replicate to significantly higher titers than D614 viruses on hNEC cultures, 




MATERIALS AND METHODS 
Cell Lines 
Vero E6/Transmembrane serine protease 2 (TMPRSS2) cells were cultured in DMEM 
supplemented with 10% FBS, 100U/mL penicillin with 100µg/mL streptomycin, and 1mM 
sodium pyruvate (Sigma-Aldrich) at 37˚C with 5% CO2. 
 Human nasal epithelial cell (hNEC) cultures were isolated from the disease-free nasal 
tissue collected during endoscopic sinus surgery mandated for disease-unrelated conditions. The 
cells were then differentiated at the air-liquid interface (ALI) in 24-well Falcon filter inserts (0.4-
µM pore; 0.33 cm2; Becton Dickinson) at 37˚C with 5% CO2. ALI medium containing 1X ALI 
maintenance supplement (STEMCELL Technologies), 0.192 µg/mL hydrocortisone stock 
solution (STEMCELL Technologies), and 5 IU/mL 0.2% heparin solution (STEMCELL 
Technologies) was used as basolateral medium. 
Virus - Seed Stock and Working Stock  
SARS-CoV-2 (isolate SARS-CoV-2/USA-Washington 1/2020) was provided by the CDC 
through BEI Resources. SARS-CoV-2/USA/MDHP-31/2020 (HP-31), SARS-CoV-
2/USA/MDHP-76/2020 (HP-76), SARS-CoV-2/USA/DCHP-7/2020 (HP-7) and SARS-CoV-
2/USA/MDHP-20/2020 (HP-20) were isolated from nasal swabs collected at Johns Hopkins 
Hospital. To produce seed stocks, virus was diluted to an MOI of 0.01 TCID50 units/cell in IM. 
Approximately 75% confluent T-150 (150 cm2) flasks of TMPRSS2 cells were then washed 
twice with PBS + and infected with 5mL/flask of inoculum, rocking every 10 minutes for 1 hour 
at 32˚C with 5% CO2. Each flask was then given 20mL of IM, incubated at 32˚C, and the 
progression of CPE monitored daily. Virus containing supernatant was collected when 70-90% 
CPE was achieved, approximately 4 days post infection. Infectious viral titer of the seed stocks 
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was then determined using TCID50 assays. Working stocks were produced in the same fashion 
using the steed stock to generate the viral inoculum.  
TCID50 Assay 
SARS-CoV-2 TCID50 assays were conducted using 96-well plates of 75% confluent 
TMPRSS2 cells. After the cells were washed twice with PBS+, ten-fold serial dilutions of each 
virus in IM were produced, and 20µL applied to 6 wells of cells. The plates were then incubated 
at 37˚C with 5% CO2 for 5 days. The cells were then fixed with 4% formaldehyde in PBS 
overnight and stained with Napthol Blue Black overnight. The resulting CPE was scored visually 
and the TCID50 value for each sample was calculated using the Reed-Muench calculation 
63. 
Low MOI hNEC GC 
Fully differentiated hNEC cells cultured on transwells in 24-well plates had their 
basolateral media collected and their apical surfaces washed three times by repeating the process 
of adding 100µL of IM with no NAT (IM-NAT), incubating for 10 minutes at 32˚C or 37˚C  
with 5% CO2, then aspirating. The cells were then infected by adding 100µL of SARS-CoV-2 
diluted to a MOI of 0.1 in IM-NAT to the apical surface for 2 hours at 32˚C or 37˚C with 5% 
CO2. Following infection, the cells were washed three times with PBS- and then incubated at 
32˚C or 37˚C with 5% CO2. Apical samples were taken at 1, 12, 24, 36, 48, 72, 96, 120, 144, and 
168 hours post infection by applying 100µL of IM-NAT to the apical surface, incubating at 32˚C 
or 37˚C for 10 minutes, and collecting. Basolateral supernatants were collected and replaced 
every 48 hours. Infectious viral titer was then quantified using TCID50 assays. 
Statistical Analysis 
 Low MOI GCs were analyzed by mixed ANOVA with repeated measures followed by a 







Impact of the D614G mutation on SARS-CoV-2 replication in the upper versus lower 
respiratory tract 
 Viruses SARS-CoV-2/USA/MDHP-31/2020 (HP-31) and SARS-CoV-2/USA/MDHP-
76/2020 (HP-76) have aspartic acid at position 614 (D614) and represent the viral population 
prior to the mutation event. SARS-CoV-2/USA/DCHP-7/2020 (HP-7) and SARS-CoV-
2/USA/MDHP-20/2020 (HP-20) are variant viruses that possess a glycine at position 614 
(G614). In order to compare the ability of pre- and post-mutation viruses to replicate in 
conditions consistent with the human upper versus lower respiratory tract, low MOI growth 
curves were conducted on hNEC cultures at either 32˚C or 37˚C.  
 Growth curves conducted at 32˚C were unsuccessful for all four viruses. Of the three 
growth curves conducted, the first (32 GC#1) has been evaluated in full (Figure 2A). HP-20 was 
the only virus found to be capable of infecting the hNECs and only half of the wells inoculated 
with the virus showed signs of viral replication. The remaining wells for all four viruses did not 
generate titers detectable by TCID50 assay. In order to avoid wasting resources on more failed 
experiments, only the inoculum and 48 hpi timepoints of the remaining two growth curves (32 
GC#2 and #3) were titered (Figure 2B). Compared to 32 GC#1, more wells became infected in 
32 GCs #2 and #3. However, HP-7 continued to have challenges infecting the hNEC cultures, as 
indicated by its position at or near the LOD. Additionally, titers for all four viruses at 48 hpi 
were lower than anticipated; at this point in infection, the virus is expected to be undergoing 
exponential replication, therefore the titer should be well above the initial, low MOI inoculum. 
Growth curves conducted at 37˚C (37 GCs #1 and #2) were successful. In 37 GC#1 (Figure 
3A), all four viruses showed exponential growth, reaching peak titer at 48 hpi. Though the 
viruses replicated similarly up until 48 hpi, D614 viral titers decreased at a significantly faster 
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rate than the G614 viruses. Though only inoculum and 48 hpi timepoints were titered for the 
second growth curve conducted at 37˚C (37 GC#2), exponential growth was observed for all four 
viruses and all wells became infected with virus (Figure 3B). Overall, these findings indicate that 
all four viruses were capable of effectively infecting hNEC cultures at 37˚C and suggest that 




















Figure 2. 32˚C growth curves comparing D614 and G614 viral replication on hNECs. Multi-
step growth curves performed on differentiated hNEC cultures infected with an MOI of 0.1 at 
32˚C. (A) Fully titered GC #1 demonstrating limited infection of hNEC cultures. (B) Inoculum 
and 48 hpi titers for GCs #2 and 3 illustrating improved but substandard infection of hNECs and 









32C Low MOI hNEC Growth Curve #1





















32C Low MOI hNEC Growth Curve #2





















32C Low MOI hNEC Growth Curve #3







































Figure 3. 37˚C growth curves comparing D614 and G614 viral replication on hNECs. (A) 
Multi-step growth curve performed on differentiated hNEC cultures infected with an MOI of 0.1 
at 37˚C (37 GC#1). Statistical significance was measured using a MANOVA with repeated 
measures followed by a Tukey’s post-test. Results are from one experiment with four biological 
replicates. **p<0.01, ***p<0.001, ****p<0.0001. L.O.D = 2.37 log TCID50/mL. (B) Inoculum 
and 48 hpi titers for 37 GC #2, illustrating consistent infection of hNECs and high viral titers for 
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Impact of the D614G mutation on SARS-CoV-2 replication kinetics in hNECs at 32˚C and 
37˚C  
 In early April 2020, SARS-CoV-2 viruses containing a mutation in the spike protein, 
D614G, became the dominant virus lineage, suggesting the mutation conferred an advantage 
over the original virus70. To understand the implications of the D614G mutation on SARS-CoV-
2 replication at temperatures representative of the upper (32˚C) and lower (37˚C) respiratory 
tract, low MOI hNEC growth curves comparing D614 and G614 viruses were carried out. Our 
preliminary data suggests that all four viruses productively infect hNEC cultures at 37˚C but fail 
to replicate efficiently at 32˚C. Further quantification of viral titers over the course of infection 
are needed to fully elucidate the effect of the D614G mutation on viral replication. 
 Several articles investigating the implications of the D614G mutation have been 
published over the course of the pandemic. In the seminal paper raising concerns about this 
variant, the authors attributed the prolific spread of G614 viruses to higher infectivity as 
indicated by replication to higher viral titers and higher patient Ct values suggesting higher in 
vivo viral loads70. The mechanism by which G614 viruses are able to generate higher viral loads 
is currently being investigated. In a paper by Daniloski et al.136, SARS-CoV-2-psueudotyped 
lentiviral particles produced using site-directed mutagenesis demonstrated G614 viruses were 
significantly more effective at entering human cells. Though ACE2 receptor binding was almost 
identical between the viruses, the G614 spike was found to be resistant to proteolytic cleavage 
during protein production, suggesting that these viruses are more infectious due to the presence 
of more functional (uncleaved) S protein per virion134,136. Other articles agree that D614G 
confers enhanced cellular entry, but indicate that higher affinity for ACE2, rather than protection 
from cleavage, is responsible for the advantage133,137. Overall, the greater infection efficiency 
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conveyed by D614G is currently considered a leading hypothesis explaining the domination of 
G614 variants in viral populations world wide138–140. 
 The clinical implications of the D614G mutation are thought to be limited. Several 
studies have shown patients infected with G614 versus D614 viruses do not show evidence of 
increased disease severity70,141. Additionally, convalescent plasma generated in response to D614 
infection has been shown to be cross protective against G614 infection, suggesting current 






Impact of the D614G mutation on SARS-CoV-2 replication kinetics in hNECs at 37˚C  
 The preliminary data generated by this study demonstrated that both D614 and G614 
viruses are susceptible to variations in temperature, lacking efficient replication at 32˚C. 
However, the goal of this study was to determine whether the D614G mutation altered viral 
fitness in conditions consistent with the upper and lower respiratory tract. In order to accomplish 
this, the conditions of the 32˚C growth curves must be altered to maximize viral infectivity and 
the remaining 37˚C growth curves must be titered. Therefore, it is necessary to identify 
alterations in the low MOI GC protocol that may allow for the success of the 32˚C GCs. 
TMPRSS2 growth curves further exploring in the impact of 32˚C and testing alterations in MOI 
need to be conducted to optimize these conditions and then apply them to hNECs. Since our 
virus working stocks are generated by infection VeroTMPRSS2 cells at 32˚C with a low MOI, I 
hypothesize that the inability to efficiently infect hNECs at that temperature has to do with the 
infection of epithelial cells rather than a strict inability to infect because of temperature. 
Additionally, we preliminarily showed that all four viruses tested were capable of 
efficient replication on fully differentiated hNEC cultures at 37˚C, with G614 viruses 
maintaining significantly higher titers for more prolonged periods of time in comparison to D614 
viruses. In order to confidently discern differences between D614 and G614 viruses at this 
temperature, GCs #2 and #3 must be titered. By optimizing the 32˚C GCs and comparing them to 
fully titered 37˚C GCs we will be able to observe the effect of the D614G mutation on viral 
replication kinetics in a cell culture system representative of the human upper respiratory tract. 
 Also, in this study we are relying on TCID50 assays which only provide information on 
the amount of infectious virus. Further studies comparing genome copies to plaque forming units 
(PFU) may be necessary to determine whether the D614G mutation is impacting viral replication 
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resulting the generation of more viral particles [more genomes and more PFUs] or whether it 
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